Segment information

6 Months Ended

Jun. 30, 2016

Segment information [Abstract]

Segment information

10. Segment information

On August 6, 2015, the Company announced its plan to separate into two independent publicly-traded companies, one a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives and the other a global specialty life sciences company focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats. In anticipation of the spin-off, the Company realigned certain components of its biosciences business to the new Aptevo segment.  Effective January 1, 2016, the Company changed its segment presentation to reflect this new structure, and prior periods have been recast to conform to the new presentation.

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Aptevo. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the CODM. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments offer different products, product candidates, manufacturing processes and services, development processes, sales and marketing processes, and are managed separately.

The Biodefense division consists of three business units: vaccines and therapeutics, medical devices and contract manufacturing. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Aptevo division consists of one business unit, which is focused on: the discovery, development, commercialization and sale of novel oncology and hematology therapeutics.

	Reportable Segments
(in thousands)	Biodefense			Aptevo			Total
Three Months Ended June 30, 2016
External revenue	$	91,254		$	10,233		$	101,487
Intersegment revenue (expense)		1,844			(1,844	)		-
Income (loss) from operations		(1,323	)		(12,297	)		(13,620	)
Three Months Ended June 30, 2015
External revenue	$	119,022		$	7,090		$	126,112
Intersegment revenue (expense)		2,130			(2,130	)		-
Income (loss) from operations		41,694			(20,242	)		21,452
Six Months Ended June 30, 2016
External revenue	$	194,223		$	18,266		$	212,489
Intersegment revenue (expense)		2,418			(2,418	)		-
Income (loss) from operations		21,693			(26,752	)		(5,059	)
Total assets		945,058			111,408			1,056,466
Six Months Ended June 30, 2015
External revenue	$	171,169		$	18,576		$	189,745
Intersegment revenue (expense)		2,234			(2,234	)		-
Income (loss) from operations		23,198			(30,056	)		(6,858	)
Total assets		820,503			122,820			943,323